The historical rank and industry rank for Big Pharma Split's Net Margin % or its related term are showing as below:
TSX:PRM'
s Net Margin % Range Over the Past 10 Years
Min: -47.23 Med: 79.36 Max: 90.58
Current: 90.55
TSX:PRM's Net Margin % is not ranked
in the Asset Management industry.
Industry Median: 84.895
vs TSX:PRM: 90.55
Big Pharma Split (TSX:PRM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Big Pharma Split Net Margin % Related Terms
Big Pharma Split Net Margin % Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split Net Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's Net Margin % distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a Net Margin % of 95.09% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Big Pharma Split and its competitors. This is 20% above median its historical median of 79.36.
Is Big Pharma Split's Net Margin % too high?
Big Pharma Split's current Net Margin % of 95.09% is 20% above median its 10-year median of 79.36. The Asset Management industry median Net Margin % is 84.90. Big Pharma Split's value of 95.09% is 12% above this industry median. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Net Margin % compare to BLK and BX?
Big Pharma Split's Net Margin % of 95.09% can be compared against companies in the Asset Management industry. The industry median Net Margin % is 84.90. Big Pharma Split's value of 95.09% is 12% above this benchmark. While the company's 10-year median is 79.36 vs. the industry median of 84.90, Big Pharma Split has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for an Asset Management company?
The median Net Margin % among Asset Management companies is 84.90, based on 1,576 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Big Pharma Split's current Net Margin % of 95.09% is 12% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median Net Margin % is 84.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current Net Margin % is 95.09%, which is 20% above median its own 10-year median of 79.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Net Margin % of 95.09%. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Net Margin % is 95.09%, which is 20% above median its 10-year median of 79.36 and 12% above the Asset Management industry median of 84.90. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Net Margin % is 95.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
Net Margin %: 95.09% (20% above median its 10-year median of 79.36)
GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
Industry Position: 12% above the Asset Management median
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for TSX:PRM
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
